New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
18:33 EDTEXPR, CPST, OCLS, JDSU, FNSR, XEC, AMD, INTC, NKTR, ARO, AXASOn The Fly: After Hours Movers
HIGHER: Express (EXPR), up 21.33% after Sycamore Partners seeks to acquire remaining shares... Aeropostale (ARO), up 7.78%... Nektar Therapeutics (NKTR), up 10.77% after AADPAC voted that the FDA should not require cardiovascular outcomes trials for the peripherally-acting mu-opioid receptor antagonist class of drugs... Intel (INTC), up 5.33% after raising quarterly and fiscal 2014 outlook... Advanced Micro Devices (AMD), up 2.1%... Cimarex Energy (XEC), up 1.5%. DOWN AFTER EARNINGS: Finisar (FNSR), down 21.8% after reporting quarterly results... JDS Uniphase (JDSU), down 3.47%... Oculus (OCLS), down 2.74% after reporting fourth quarter results... Capstone Turbine (CPST), down 1.9%. ALSO LOWER: Abraxas Petroleum (AXAS), down 1.35% after commencing a 10M share common stock offering.
News For EXPR;ARO;NKTR;INTC;AMD;XEC;FNSR;JDSU;OCLS;CPST;AXAS From The Last 14 Days
Check below for free stories on EXPR;ARO;NKTR;INTC;AMD;XEC;FNSR;JDSU;OCLS;CPST;AXAS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 19, 2014
08:14 EDTEXPRExpress downgraded to Neutral from Buy at Goldman
Goldman downgraded Express to Neutral based on lackluster fundamentals as the pace of promotions in the quarter indicate a less robust margin recovery. The analyst believes shares reflect fundamentals and upside risk of a potential takeover. Price target lowered to $17 from $18.
07:42 EDTINTCIntel dividend can rise up to 45% over next two years, says Jefferies
Subscribe for More Information
06:00 EDTAMDStocks with implied volatility top IV index mean; AMD IBM
Stocks with implied volatility top IV index mean; AMD (AMD) 55, IBM (IBM) 61 according to iVolatility.
September 18, 2014
18:25 EDTAMDOn The Fly: After Hours Movers
HIGHER: Concur (CNQR), up 19.5% after SAP (SAP) announced that it will acquire the company for $129 per share... Navidea Biopharmaceuticals (NAVB), up 9.8% after confirming FDA orphan designation for Lymphoseek... Molycorp (MCP), up 6.1% after Oaktree Capital reported a 9.1% passive stake in the company... JetBlue (JBLU), up 4.6% following CEO transition announcement... Wendy's (WEN), up 2.15% after Trian reported a 24.39% stake in the company... Sears Holdings (SHLD), up 2.6% after Fairholme Capital reported a 24% stake in the company... AMD (AMD), up 1% after announcing that it expanded an IP partnership with Synopsys (SNPS). DOWN AFTER EARNINGS: Red Hat (RHT), down 3%... Oracle (ORCL), down 2.4% following first quarter earnings miss and CEO transition... Tibco Software (TIBX), down 5.5%. ALSO LOWER: Quest Resource (QRHC), down 13.4% after filing an automatic common stock and warrant shelf... Eagle Rock (EROC), down 4.5% after filing to sell 53.34M common units for limited partners... Chatham Lodging (CLDT), down 3.3% after filing to sell 5M shares of common stock... Glu Mobile (GLUU), down 2.3% after filing to sell 9.98M shares of common stock for holders... Blackstone Mortgage (BXMT), down 1.6% after filing to sell 8M shares of common stock.
17:03 EDTAMDAMD, Synopsys expand IP partnership
Subscribe for More Information
11:56 EDTFNSRFinisar management to meet with Barrington
Meetings to be held in Portland, OR on September 23 and in Seattle on September 24 hosted by Barrington.
08:35 EDTCPSTCapstone Turbine announces 2 MW order for offshore platform
Capstone Turbine announced that it received an order for two C1000 microturbines for an offshore oil and gas platform in Africa. The two C1000s will run on flare gas to power artificial lift equipment, more specifically electrical submersible pumps that are used to increase oil production. The artificial lift market was more than $9.2B in 2012 and is forecasted to grow to $16B in 2018. Africa and the Middle East are expected to represent 13% of this growth year over year.
06:50 EDTINTCIntel, Spreadtrum may enter partnership to develop x86 products, DigiTimes says
Intel is looking to promote x86 architecture to China chip designers and may enter a partnership with Spreadtrum, reports DigiTimes Research. The cooperation would allow Intel to fill some of its empty capacity while Spreadtrum would gain advantages from Intel's advanced manufacturing processes to reduce costs. Reference Link
05:56 EDTAMDStocks with implied volatility top IV index mean; AMD BBRY
Subscribe for More Information
September 17, 2014
08:50 EDTNKTRNektar Movantik approval positive, says Roth Capital
Subscribe for More Information
07:35 EDTAXASImperial Capital to hold a conference
Subscribe for More Information
05:55 EDTAMDStocks with implied volatility top IV index mean; AMD ADBE
Subscribe for More Information
September 16, 2014
14:33 EDTNKTRNektar price target raised to $20 from $18 at Brean Capital
Subscribe for More Information
13:22 EDTNKTRNektar approval improves risk/reward, says Piper Jaffray
Piper Jaffray says today's FDA approval of Movantik improves the risk/reward on shares of Nektar. Piper expects Movantik to be one of a series of successes for the company and reiterates an Overweight rating on the stock with a $20 price target. The firm says the post-marketing study required by the FDA to evaluate potential cardiovascular risks was expected.
13:17 EDTNKTRNektar up 3% after FDA approves Movantik for treatment of OIC
Subscribe for More Information
12:37 EDTNKTRNektar reports FDA approval of MOVANTIK for treatment of OIC
Nektar Therapeutics (NKTR) reported that partner AstraZeneca (AZN) announced that the FDA approved MOVANTIK tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist medication for the treatment of opioid-induced constipation, or OIC, in adult patients with chronic, non-cancer pain. In line with the recommendation from the FDA Anesthetic and Analgesic Drug Products Advisory Committee that took place in June, AstraZeneca has agreed to conduct a post-marketing, observational epidemiologic cardiovascular safety study for MOVANTIK. MOVANTIK is expected to be available to patients in the first half of 2015. MOVANTIK is currently a schedule II controlled substance because it is structurally related to noroxymorphone. During the review of the New Drug Application, the FDA evaluated the abuse potential of MOVANTIK and the approved labelling indicates that MOVANTIK has no risk of abuse or dependency. AstraZeneca submitted a petition for the descheduling of MOVANTIK to the U.S. Drug Enforcement Administration, or DEA, in March 2012, which was accepted for review and will be considered by the DEA as part of the process for addressing the descheduling request.
10:19 EDTNKTRFDA approves Movantik with requirement for cardiovascular risk study
Subscribe for More Information
10:11 EDTNKTRNektar trading halted, pending news
08:09 EDTOCLSOculus awarded four new patents for Microcyn technology
Subscribe for More Information
08:00 EDTNKTRFDA PDUFA Date for Nektar and AstraZeneca''s Movantik is September 16, 2014
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use